Due to potential risks of medullary thyroid carcinoma and multiple endocrine neoplasia, its not recommended for individuals with a personal or family history of these conditions [45]
The SELECT trial demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) by 20% in adults with overweight or obesity and established heart disease (Lincoff et al., SELECT trial, New England Journal of Medicine , 2023)
While there is a potential for side effects like nausea, digestive discomfort, and fatigue, many patients find the pros outweigh the cons
doi: 10.1007/s13205-021-02738-3 52 SebastiaoICandeiasESantosMSde OliveiraCRMoreiraPIDuarteAI
Regular check-ins allow your provider to assess progress, monitor key health metrics, and make any necessary adjustments to ensure your treatment stays effective
For prior authorization to be approved for a GLP-1 medication, we will need to provide specific information about your medical condition and treatment history